Breaking Down Religare Enterprises Limited Financial Health: Key Insights for Investors

Religare Enterprises' latest results present a striking mix of momentum and caution: consolidated revenue climbed to ₹2,028.4 crore in Q4FY25 (up 9.3% YoY) and full-year revenue rose 10.59% to ₹974.49 crore, even as sales in Q4 fell to ₹236.35 crore and consolidated net profit plunged 46.25% year-on-year to ₹125.19 crore for FY25; investors will want to weigh a ₹7,567.01 crore market capitalization with a lofty P/E of 82x (versus a sector average of 23x), 39.72% stock volatility and a beta of 1.35 against balance-sheet strengths such as a net worth of ₹2,516 crore, a debt-to-equity of 0.09x and subsidiary Religare Finvest turning debt-free with a CAR of 197.6% and ~1% net NPA-alongside growth engines like Care Health Insurance's gross written premium of ₹8,56,199 lakh (up 22% YoY) and Religare Broking's revenue rise to ₹38,306.71 lakh-while margins and profitability metrics (OPM swings, ROE down to 4.97% from 9.96%, net profit margin 2.5%) and an Altman Z-score of 2.03 raise clear risk-reward questions that demand a closer look

Religare Enterprises Limited (RELIGARE.NS) - Revenue Analysis

• Consolidated revenue (Q4FY25): ₹2,028.4 crore (up 9.3% YoY from ₹1,855.68 crore in Q4FY24).
• Full fiscal year revenue (FY25): ₹974.49 crore (up 10.59% from ₹881.19 crore in FY24).
• Care Health Insurance gross written premium (FY25): ₹8,56,199 lakh (≈₹8,561.99 crore) - 22% YoY growth.
• Religare Broking Limited consolidated revenue (FY25): ₹38,306.71 lakh (≈₹383.07 crore) - up 3.6% YoY.
• Quarterly sales decline: Sales fell 5.43% to ₹236.35 crore in Q4FY25 from ₹249.91 crore in Q4FY24.
• Market capitalization: ₹7,567.01 crore; 52-week high ₹319.9, 52-week low ₹201.

• Key revenue drivers: insurance GWP growth (Care Health), steady broking income, and consolidated business recoveries contributing to FY25 topline expansion.
• Near-term watchpoints: quarterly sales contraction in Q4FY25 and how segment mix (insurance vs broking vs other revenues) affects margins and cash flows.

Religare Enterprises Limited (RELIGARE.NS) - Profitability Metrics

• Q4FY25 consolidated net profit: ₹151.3 crore (down 17% from ₹181.0 crore in Q4FY24).
• FY25 consolidated net profit: ₹125.19 crore (down 46.25% from ₹232.91 crore in FY24).
• Return on Equity (ROE) FY25: 4.97% (vs 9.96% in FY24).
• Profit Before Tax (PBT) FY25: ₹243.30 crore (up 12% from ₹217.34 crore in FY24).
• Operating profit margin (OPM) in Q4FY25: 98.34% (reported as a decrease of 30.76% vs 49.18% in Q4FY24).
• Net profit margin FY25: 2.5% (vs 5.6% in FY24).

• Disparity between rising PBT and falling net profit suggests higher taxation, exceptional/one‑off charges, or increased non‑operating losses absorbing pre‑tax gains in FY25.
• ROE halving to ~5% indicates reduced shareholder returns and potential dilution of profitability relative to equity base.
• Sharp drop in net profit margin (5.6% → 2.5%) reflects compression of bottom‑line efficiency despite PBT improvement.
• Q4 OPM movement (49.18% → 98.34%) should be investigated for reporting or classification changes given the atypical jump alongside overall margin weakness.

Religare Enterprises Limited (RELIGARE.NS) - Debt vs. Equity Structure

• Religare Finvest Limited (subsidiary) reported debt-free status as of March 2025, with a Capital Adequacy Ratio (CAR) of 197.6% and a net NPA ratio of ~1%.
• Total assets and total liabilities both expanded by 18.6% year-on-year to ₹111,754 crore in FY25 (from ₹94,226 crore in FY24), indicating proportional growth in scale.
• Debt-to-equity ratio: 0.09x in FY25 - reflecting conservative leverage and substantial financial flexibility.
• Net worth stood at ₹2,516 crore in FY25, supporting capitalization and loss-absorption capacity.
• Current liabilities increased 23.4% to ₹75,838 crore in FY25 (from ₹61,458 crore in FY24), signaling higher near-term obligations.

• Implications for investors: low group-level leverage (0.09x) combined with a debt-free subsidiary and high CAR suggests resilience to credit shocks and room for strategic capital deployment.
• Watchpoints: the 23.4% rise in current liabilities increases near-term liquidity management importance despite strong capitalization.

Religare Enterprises Limited (RELIGARE.NS) - Liquidity and Solvency

• Operating profit margin (OPM): reported as 98.34% in Q4FY25 vs 49.18% in Q4FY24 - a stated decrease of 30.76% (reported movement).
• Net profit margin: 2.5% in FY25, down from 5.6% in FY24.
• Altman Z-score: 2.03 - indicates moderate financial stability (neither clearly distressed nor strongly safe).
• Operating cash flow: improved in FY25, supporting near-term liquidity and capacity for growth investments.
• Current assets: decreased 56% to ₹24,399 crore in FY25 from ₹55,135 crore in FY24.
• Fixed assets: increased 123% to ₹87,355 crore in FY25 from ₹39,090 crore in FY24.

• The sharp decline in current assets alongside a large rise in fixed assets signals a significant asset mix shift - higher capital deployment or reclassification that warrants scrutiny of cash conversion and asset quality.
• Margin dynamics (OPM anomaly vs net margin drop) suggest operating accounting, one‑off items, or changes in segment mix; reconcile QoQ and FY disclosures to understand true operating profitability.
• Altman Z‑score at 2.03 provides moderate comfort but is sensitive to the large balance-sheet changes; continued monitoring of cash flow generation and working-capital trends is essential.
• Improved operating cash flow is a positive offset to the current-asset decline, indicating capacity to fund near-term obligations and selective investments.
• Watch liquidity ratios, receivables aging, and fixed-asset capitalization notes in the next filings to assess solvency trajectory.

Religare Enterprises Limited (RELIGARE.NS) - Valuation Analysis

• Price-to-Book (P/B): 3.09 (up 4.75% from 2.95 year-over-year)
• Price-to-Earnings (P/E): 82x (sector average: 23x)
• Market capitalization: reported figures of ₹7,567.01 crore and an alternate reported figure of ₹8,420 crore (peer-group positioning: above median)
• 52‑week range: High ₹319.9 | Low ₹201
• Stock volatility (annualized): 39.72%
• Beta: 1.35

• Valuation implications: The 82x P/E signals investor willingness to pay a significant premium for current earnings or expected growth - mismatch with sector multiple suggests either growth expectations, limited current earnings base, or valuation stretch.
• Balance-sheet lens: A P/B of 3.09, rising year-over-year and materially above the reported six-year average (-6.55), implies investors value intangible drivers or anticipate improved book returns; reconcile with asset quality and capital adequacy metrics before inferring safety.
• Risk profile: Volatility of 39.72% and beta 1.35 point to elevated price risk - position sizing and stop-loss discipline are relevant for investors.

Religare Enterprises Limited (RELIGARE.NS) - Risk Factors

• Declining profitability: ROE fell to 4.97% in FY25 from 9.96% in FY24, and net profit margin dropped to 2.5% in FY25 from 5.6% in FY24.
• Sharp contraction in operating performance: Operating profit margin (OPM) decreased by 30.76% year-on-year in Q4FY25, registering 98.34% versus 49.18% in Q4FY24.
• Valuation premium risk: P/E ratio at 82x versus sector average of 23x implies elevated expectations and sensitivity to earnings misses.
• Market and equity risk: High stock volatility of 39.72% and beta of 1.35 suggest amplified share-price swings relative to the market.
• Moderate financial distress signal: Altman Z-score of 2.03 points to moderate financial stability-below the safe zone, above distress threshold.
• Execution and capital allocation: Lower ROE and margins raise concerns on capital efficiency, cost control, and future return generation.
• Liquidity and funding: Given margin compression and elevated valuation, refinancing or raising capital in adverse markets could be costly.
• Sector and macro sensitivity: As a financial-services player, earnings remain exposed to interest-rate cycles, credit trends, and regulatory shifts.

• Investor implications: elevated valuation + falling ROE and margins increase downside risk if growth or margins disappoint.
• Risk management focus: monitor cash flows, credit costs, capital adequacy, and any shifts in regulatory landscape affecting business lines.
• Triggers to watch: quarterly earnings volatility, changes in interest-rate environment, material asset-quality shifts, and any equity raises or dilutive financings.

Religare Enterprises Limited (RELIGARE.NS) - Growth Opportunities

• Care Health Insurance (insurance arm) delivered a gross written premium of ₹8,56,199 lakh in FY25, up 22% year-on-year - signaling robust underwriting and premium momentum in the retail health insurance segment.
• Religare Broking Limited reported consolidated revenue of ₹38,306.71 lakh in FY25, a 3.6% increase, indicating steady fee and brokerage income growth amid evolving capital markets activity.
• Consolidated revenue for Religare Enterprises rose 9.3% year-on-year to ₹2,028.4 crore in Q4FY25, reflecting quarter-end operational acceleration and improved fee/interest income mix.
• Total assets expanded 18.6% to ₹111,754 crore in FY25 (from ₹94,226 crore in FY24), supporting higher lending/investment capacity and cross-sell opportunities.
• Net worth stood at ₹2,516 crore in FY25, underscoring strong capitalization to absorb risk and fund growth initiatives.
• Market capitalization was ₹7,567.01 crore with a 52-week trading range of ₹201 (low) to ₹319.9 (high), reflecting market valuation and trading volatility to monitor for entry/exit timing.

• Strategic levers: scaling Care Health's retail distribution, cross-selling insurance through broking and lending channels, leveraging a larger asset base for higher-yield lending, and optimizing capital allocation given ₹2,516 crore net worth.
• Investor signals: improved quarterly revenue (+9.3% Q4FY25) and FY25 asset expansion (+18.6%) support organic growth, while market cap and 52-week range highlight potential valuation upside for long-term investors.
• Operational focus areas: margin expansion in broking, claims and underwriting discipline in health insurance, and efficient capital usage to convert asset growth into sustainable ROE improvements.